Ovarian Cancer Patients may Be Benefited by Investigational Drug

women with recurrent ovarian cancer can be helped by giving an investigational drug in combination with chemotherapy.

New results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm reveal that women with recurrent ovarian cancer can be helped by giving an investigational drug in combination with chemotherapy.

Dr. Bradley Monk, a UC Irvine gynecologic oncologist who led the worldwide phase III clinical trial, said trabectedin is the most recent addition to a short list of active drug therapies for recurrent ovarian cancer.

Ovarian Cancer | Cancer in the Ovaries - Causes, Symptoms, Treatment & Prevention
Ovarian cancer affects both the ovaries and is referred to as the 'silent killer' as the symptoms go unnoticed until the disease advances.

"These are exciting results because positive trials in recurrent ovarian cancer are rare and have almost always led to federally approved treatments," said Monk, an associate professor who studies and treats ovarian cancers at the Chao Family Comprehensive Cancer Center at UC Irvine.

"This treatment undoubtedly will be evaluated carefully by the U.S. Food and Drug Administration and, if approved, will give women with ovarian cancer another much needed option,” Monk added.

Phase III studies are multicenter trials on large patient groups designed to be the definitive assessment of a drug’s effectiveness. Such a study is often the last step before a drug is reviewed by a regulatory agency like the FDA for approval as a safe, effective treatment.

About Cancer in Women
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.

In the latest trial, an international group of researchers treated 672 women whose ovarian cancer had progressed after first-line treatment. Half the women received a combination therapy of trabectedin and a chemotherapy drug called pegylated liposomal doxorubicin.

The other half received the chemotherapy drug alone, which is standard treatment in these cases.

Advertisements

Hairdressers Face High Cancer Risk from Dyes and Chemicals They Work With
Hairdressers may face an increased risk of cancer because of the dyes and other chemicals they work with, according to the World Health Organisation's International Agency for Research

In patients on the combination therapy, researchers found no progression of the cancer for an average of 7.3 months, as compared to 5.8 months for those treated with the single drug.

For those who had relapsed more than six months after the first-line therapy, the median progression-free time was 9.2 months for the combination treatment, as compared to 7.5 months for the other patients.